Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Tapentadol Tablets For Moderate To Scute Pain In Over 18s Now Available For Use In The United States
German pain expert company GrÃønenthal GmbH announces that the new centrally acting analgesic tapentadol is now available in the United States. The drug is indicated for the relief of moderate to severe acute pain in patients 18 years of age and older. Approval was given by the US Food and Drug Administration (FDA) in November 2008 for tapentadol (NUCYNTATM) tablets. With the cooperation of GrÃønenthal and its marketing partner Ortho-McNeil-Janssen Pharmaceuticals, Inc., the medication can now be prescribed by physicians and other appropriate health care professionals in the United States.

Bee-Killing Parasite Genome Sequenced
Agricultural Research Service (ARS) scientists have sequenced the genome
News of the day
Expanded Testing Reveals 2000 Percent Increase In Number Of HIV-Positive Indian Children
"Expanded testing across India in the past three years shows a 2,000 percent jump in the number of HIV cases among children, [Ghulam Nabi Azad] the country"s health minister announced Wednesday," CNN reports. As of May 2009, reports found that nearly 53,000 children are living with HIV in India - up from 2,253 recorded cases in November 2006, Azad said during an address to the parliament (Singh, 7/29).
Health Insurance

EpiCept Initiates Post-Approval Clinical Study With Ceplene(R)

EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced the start of a post-approval clinical study with Ceplene® (histamine dihydrochloride) following Ethics Committee and Competent Authority approvals in Sweden, Belgium, and France. This study will fulfill the post approval commitments requested by the European Medicines Evaluation Agency (EMEA) in granting marketing authorization. Ceplene® is indicated for remission maintenance in adult patients with Acute Myeloid Leukemia (AML) in first remission. Ceplene®is to be administered in conjunction with low-dose interleukin-2 (IL-2). This study will enroll up to 150 patients at approximately 25 centers across Europe with sites in Sweden, Belgium, France, the U.K., Spain and Italy. The two primary objectives are to further demonstrate the clinical pharmacology of Ceplene® by assessing certain immunologic biomarkers in AML patients in first remission, and to measure the effect of Ceplene®/IL-2 on minimal residual disease in the same patient population. Secondary objectives will assess leukemia-free survival after a follow-up period of up to two years. EpiCept expects the study will take approximately three years to complete. "We are pleased to begin this study under the leadership of study chair and principal investigator Dr. Robin Foa in Rome, Italy and co-principal investigator Dr. Mats L. Brune in Gothenburg, Sweden and to be working closely with a broad network of hematology thought leaders," stated Jack Talley, President and Chief Executive Officer of EpiCept. "The commencement of this trial meets our post-approval commitment to the EMEA and underscores our determination to move forward as quickly as possible with the commercial launch of the drug in the European Union. Ceplene® is an important therapy for AML patients because it is the only medical therapy ever proven to prevent relapse in this deadly disease." About Ceplene® Ceplene® is EpiCept"s proprietary product approved in the European Union for maintenance therapy for adult patients with AML in first remission. Ceplene® is designed to protect lymphocytes responsible for immune-mediated destruction of residual leukemic cells. Laboratory research has demonstrated that Ceplene® reduces formation of oxygen radicals from phagocytes, inhibiting NADPH oxidase and protecting IL-2-activated NK-cells and T-cells. In October 2008 Ceplene® received full marketing approval in the European Union for maintenance therapy and prevention of relapse in adult patients with AML in first remission. EpiCept Corporation


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009